Corcept Therapeutics vs Pacira BioSciences
Corcept Therapeutics reported revenue of $761 million in fiscal 2025, about the same as Pacira BioSciences' $726 million in fiscal 2025. Corcept Therapeutics' revenue grew 12.8% in its latest year, and Pacira BioSciences' grew 3.6%. Corcept Therapeutics had an operating margin of 5.9%, against 2.6% at Pacira BioSciences. Free cash flow was $142 million at Corcept Therapeutics and $137 million at Pacira BioSciences.
Side by side
| Corcept Therapeutics | Pacira BioSciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $761M | $726M |
| Revenue growth | 12.8% | 3.6% |
| Revenue growth a year, last 5 years | 16.6% | 11.1% |
| Gross margin | 98.3% | 79.4% |
| Operating margin | 5.9% | 2.6% |
| Net margin | 13.1% | 1.0% |
| Free cash flow | $142M | $137M |
| Free cash flow margin | 18.6% | 18.8% |
| Return on capital | 15.7% | 1.1% |
| Net debt to EBITDA | −8.1x | 1.2x |
| Dividends and buybacks | $173M | $148M |
| Change in diluted share count | 5.7% | −2.6% |
| Last close | $72.77 | $36.43 |
| P/E at the last close | 57.3× | 39.2× |
| Insider trades, last 12 months | bought $3.3 million, sold $92.5 million | sold $2.5 million |
| Piotroski F-score | 3 of 9 | 9 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Corcept TherapeuticsPacira BioSciences
Operating margin
Percent of revenue
Corcept TherapeuticsPacira BioSciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Corcept TherapeuticsPacira BioSciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Corcept Therapeutics and Pacira BioSciences pages.